2026 Q2 - tulosraportti
Vain PDF
35 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 14.8. | ||
2026 Q1 - tulosraportti 15.5. | ||
Vuosittainen yhtiökokous 2026 14.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13.8.News from Cerenome: Key points in the news: New insurance coverage agreement: Cerenome has entered into an in-network provider agreement with Health Care Service Corporation (HCSC), which came into effect on August 1, 2026. The CNSide® test: The agreement covers the company's proprietary diagnostic test CNSide®, which is used to analyze cerebrospinal fluid (CSF) to detect, monitor, and guide the treatment of cancer cells that have spread to the central nervous system (leptomeningeal metastases). 27.3 million new insured individuals: HCSC is one of the largest member-owned health insurance companies in the USA and operates Blue Cross and Blue Shield plans in, among others, Texas, Illinois, Montana, New Mexico, and Oklahoma. The agreement adds approximately 27.3 million insured individuals. 2026 target reached ahead of schedule: With the HCSC agreement, Cerenome has now reached a total of approximately 153 million covered lives in the USA through their commercial and Medicare Advantage agreements. The company thereby surpasses its official target for the entire year 2026 (which was 150 million covered lives) ahead of schedule. Why is this important for the company? For diagnostic laboratory tests in the USA, in-network status with large insurance companies is crucial for: Doctors' use of the test: Doctors are much more willing to prescribe the test when patients have direct insurance coverage. Reimbursement and revenue: The company ensures stable and direct settlement from insurance companies instead of out-of-pocket payments or cumbersome approval procedures. Commercial expansion: The agreement strengthens the basis for increased commercial sales of CNSide®, which since 2020 has been performed more than 11,000 times at over 120 American cancer centers. The primary investor-related positives: Crucial commercial breakthrough: Achieving in-network status with one of the largest Blue Cross and Blue Shield companies (HCSC) means that the test effectively becomes available to 27.3 million new patients without heavy bureaucratic approval processes. Exceeds own targets (Management Execution): Reaching 153 million covered lives and thereby achieving their annual target for the entire year 2026 ahead of schedule sends a strong signal to the market that management is effectively executing their business plan. Better and faster cash flow: In-network status reduces the risk of insurance companies refusing to pay, and it shortens the time from when the test is performed until the money rolls into the coffers. https://finance.yahoo.com/healthcare/articles/cerenome-secures-network-agreement-health-113000030.html- ·21.7.Another positive news: The news is about the biotechnology company Plus Therapeutics (Nasdaq: PSTV) and their subsidiary CNSide Diagnostics, which has entered into a new regional agreement with the health insurance company Medical Mutual. Key points of the news: New coverage in the USA: The agreement came into effect on July 1, 2026, and provides health insurance coverage for approximately 1.2 million people in the states of Ohio and Kentucky. What is covered? The agreement covers the company's CNSide® test (Cerebrospinal Fluid Tumor Cell Enumeration Assay). It is a specialized laboratory test of cerebrospinal fluid (CSF) used to detect, quantify, and monitor cancer cells that have spread to the central nervous system (leptomeningeal metastases). Significant milestone: With this agreement, the CNSide test reaches a total contractual coverage of approximately 127 million people in the USA. Behind the technology and the company: The test enables doctors to diagnose faster and more accurately, tailor treatments, and monitor how cancer patients (especially with spread from breast cancer, lung cancer, or melanoma) respond to ongoing therapy. The agreement with Medical Mutual is another step in Plus Therapeutics' commercial rollout of CNSide in 2026, where they have secured agreements with both regional and national insurance companies (including Elevance Health, Blue Shield of California, and Highmark) during the year. https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-regional-coverage-113000620.html 🤝🙏
- ·14.7.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html Here's what the news means for you as an investor, broken down into the most critical points: 1. It removes the "bottleneck" for doctors The biggest problem for many biotech and diagnostics companies is not inventing a good product, but getting doctors to actually use it. Doctors slavishly follow clinical guidelines (like NCCN). Before: Doctors might have tested cerebrospinal fluid sporadically or given up because the old method was too uncertain. Now: NCCN guidelines now directly dictate that systematic testing should be done every 4 to 8 weeks during treatment. This creates a completely natural, recurring need for testing. 2. Enormous momentum for "Reimbursement" (Refusion) To make money from a medical test in the USA, insurance companies must pay for it. They typically refuse to pay if a test is not backed by official guidelines or solid data. The fact that NCCN now recommends more frequent testing makes it much easier for Plus Therapeutics to convince the remaining American insurance companies to cover CNSide. This directly supports their 2026 goal of reaching 150 million covered lives in the USA. 3. "The Razor and Blade" business model The most attractive thing about CNSide is that it is not a "one-and-done" test. Since the guidelines now recommend testing every 4-8 weeks to monitor if the treatment works, CNSide becomes a continuous revenue stream per patient. More tests per patient mean higher and more predictable revenue (recurring revenue) for the company. In short: The news significantly reduces clinical risk and paves the way for commercial growth in 2026. 🤝🤞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
35 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13.8.News from Cerenome: Key points in the news: New insurance coverage agreement: Cerenome has entered into an in-network provider agreement with Health Care Service Corporation (HCSC), which came into effect on August 1, 2026. The CNSide® test: The agreement covers the company's proprietary diagnostic test CNSide®, which is used to analyze cerebrospinal fluid (CSF) to detect, monitor, and guide the treatment of cancer cells that have spread to the central nervous system (leptomeningeal metastases). 27.3 million new insured individuals: HCSC is one of the largest member-owned health insurance companies in the USA and operates Blue Cross and Blue Shield plans in, among others, Texas, Illinois, Montana, New Mexico, and Oklahoma. The agreement adds approximately 27.3 million insured individuals. 2026 target reached ahead of schedule: With the HCSC agreement, Cerenome has now reached a total of approximately 153 million covered lives in the USA through their commercial and Medicare Advantage agreements. The company thereby surpasses its official target for the entire year 2026 (which was 150 million covered lives) ahead of schedule. Why is this important for the company? For diagnostic laboratory tests in the USA, in-network status with large insurance companies is crucial for: Doctors' use of the test: Doctors are much more willing to prescribe the test when patients have direct insurance coverage. Reimbursement and revenue: The company ensures stable and direct settlement from insurance companies instead of out-of-pocket payments or cumbersome approval procedures. Commercial expansion: The agreement strengthens the basis for increased commercial sales of CNSide®, which since 2020 has been performed more than 11,000 times at over 120 American cancer centers. The primary investor-related positives: Crucial commercial breakthrough: Achieving in-network status with one of the largest Blue Cross and Blue Shield companies (HCSC) means that the test effectively becomes available to 27.3 million new patients without heavy bureaucratic approval processes. Exceeds own targets (Management Execution): Reaching 153 million covered lives and thereby achieving their annual target for the entire year 2026 ahead of schedule sends a strong signal to the market that management is effectively executing their business plan. Better and faster cash flow: In-network status reduces the risk of insurance companies refusing to pay, and it shortens the time from when the test is performed until the money rolls into the coffers. https://finance.yahoo.com/healthcare/articles/cerenome-secures-network-agreement-health-113000030.html
- ·21.7.Another positive news: The news is about the biotechnology company Plus Therapeutics (Nasdaq: PSTV) and their subsidiary CNSide Diagnostics, which has entered into a new regional agreement with the health insurance company Medical Mutual. Key points of the news: New coverage in the USA: The agreement came into effect on July 1, 2026, and provides health insurance coverage for approximately 1.2 million people in the states of Ohio and Kentucky. What is covered? The agreement covers the company's CNSide® test (Cerebrospinal Fluid Tumor Cell Enumeration Assay). It is a specialized laboratory test of cerebrospinal fluid (CSF) used to detect, quantify, and monitor cancer cells that have spread to the central nervous system (leptomeningeal metastases). Significant milestone: With this agreement, the CNSide test reaches a total contractual coverage of approximately 127 million people in the USA. Behind the technology and the company: The test enables doctors to diagnose faster and more accurately, tailor treatments, and monitor how cancer patients (especially with spread from breast cancer, lung cancer, or melanoma) respond to ongoing therapy. The agreement with Medical Mutual is another step in Plus Therapeutics' commercial rollout of CNSide in 2026, where they have secured agreements with both regional and national insurance companies (including Elevance Health, Blue Shield of California, and Highmark) during the year. https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-regional-coverage-113000620.html 🤝🙏
- ·14.7.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html Here's what the news means for you as an investor, broken down into the most critical points: 1. It removes the "bottleneck" for doctors The biggest problem for many biotech and diagnostics companies is not inventing a good product, but getting doctors to actually use it. Doctors slavishly follow clinical guidelines (like NCCN). Before: Doctors might have tested cerebrospinal fluid sporadically or given up because the old method was too uncertain. Now: NCCN guidelines now directly dictate that systematic testing should be done every 4 to 8 weeks during treatment. This creates a completely natural, recurring need for testing. 2. Enormous momentum for "Reimbursement" (Refusion) To make money from a medical test in the USA, insurance companies must pay for it. They typically refuse to pay if a test is not backed by official guidelines or solid data. The fact that NCCN now recommends more frequent testing makes it much easier for Plus Therapeutics to convince the remaining American insurance companies to cover CNSide. This directly supports their 2026 goal of reaching 150 million covered lives in the USA. 3. "The Razor and Blade" business model The most attractive thing about CNSide is that it is not a "one-and-done" test. Since the guidelines now recommend testing every 4-8 weeks to monitor if the treatment works, CNSide becomes a continuous revenue stream per patient. More tests per patient mean higher and more predictable revenue (recurring revenue) for the company. In short: The news significantly reduces clinical risk and paves the way for commercial growth in 2026. 🤝🤞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 14.8. | ||
2026 Q1 - tulosraportti 15.5. | ||
Vuosittainen yhtiökokous 2026 14.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
35 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 14.8. | ||
2026 Q1 - tulosraportti 15.5. | ||
Vuosittainen yhtiökokous 2026 14.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13.8.News from Cerenome: Key points in the news: New insurance coverage agreement: Cerenome has entered into an in-network provider agreement with Health Care Service Corporation (HCSC), which came into effect on August 1, 2026. The CNSide® test: The agreement covers the company's proprietary diagnostic test CNSide®, which is used to analyze cerebrospinal fluid (CSF) to detect, monitor, and guide the treatment of cancer cells that have spread to the central nervous system (leptomeningeal metastases). 27.3 million new insured individuals: HCSC is one of the largest member-owned health insurance companies in the USA and operates Blue Cross and Blue Shield plans in, among others, Texas, Illinois, Montana, New Mexico, and Oklahoma. The agreement adds approximately 27.3 million insured individuals. 2026 target reached ahead of schedule: With the HCSC agreement, Cerenome has now reached a total of approximately 153 million covered lives in the USA through their commercial and Medicare Advantage agreements. The company thereby surpasses its official target for the entire year 2026 (which was 150 million covered lives) ahead of schedule. Why is this important for the company? For diagnostic laboratory tests in the USA, in-network status with large insurance companies is crucial for: Doctors' use of the test: Doctors are much more willing to prescribe the test when patients have direct insurance coverage. Reimbursement and revenue: The company ensures stable and direct settlement from insurance companies instead of out-of-pocket payments or cumbersome approval procedures. Commercial expansion: The agreement strengthens the basis for increased commercial sales of CNSide®, which since 2020 has been performed more than 11,000 times at over 120 American cancer centers. The primary investor-related positives: Crucial commercial breakthrough: Achieving in-network status with one of the largest Blue Cross and Blue Shield companies (HCSC) means that the test effectively becomes available to 27.3 million new patients without heavy bureaucratic approval processes. Exceeds own targets (Management Execution): Reaching 153 million covered lives and thereby achieving their annual target for the entire year 2026 ahead of schedule sends a strong signal to the market that management is effectively executing their business plan. Better and faster cash flow: In-network status reduces the risk of insurance companies refusing to pay, and it shortens the time from when the test is performed until the money rolls into the coffers. https://finance.yahoo.com/healthcare/articles/cerenome-secures-network-agreement-health-113000030.html
- ·21.7.Another positive news: The news is about the biotechnology company Plus Therapeutics (Nasdaq: PSTV) and their subsidiary CNSide Diagnostics, which has entered into a new regional agreement with the health insurance company Medical Mutual. Key points of the news: New coverage in the USA: The agreement came into effect on July 1, 2026, and provides health insurance coverage for approximately 1.2 million people in the states of Ohio and Kentucky. What is covered? The agreement covers the company's CNSide® test (Cerebrospinal Fluid Tumor Cell Enumeration Assay). It is a specialized laboratory test of cerebrospinal fluid (CSF) used to detect, quantify, and monitor cancer cells that have spread to the central nervous system (leptomeningeal metastases). Significant milestone: With this agreement, the CNSide test reaches a total contractual coverage of approximately 127 million people in the USA. Behind the technology and the company: The test enables doctors to diagnose faster and more accurately, tailor treatments, and monitor how cancer patients (especially with spread from breast cancer, lung cancer, or melanoma) respond to ongoing therapy. The agreement with Medical Mutual is another step in Plus Therapeutics' commercial rollout of CNSide in 2026, where they have secured agreements with both regional and national insurance companies (including Elevance Health, Blue Shield of California, and Highmark) during the year. https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-regional-coverage-113000620.html 🤝🙏
- ·14.7.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html Here's what the news means for you as an investor, broken down into the most critical points: 1. It removes the "bottleneck" for doctors The biggest problem for many biotech and diagnostics companies is not inventing a good product, but getting doctors to actually use it. Doctors slavishly follow clinical guidelines (like NCCN). Before: Doctors might have tested cerebrospinal fluid sporadically or given up because the old method was too uncertain. Now: NCCN guidelines now directly dictate that systematic testing should be done every 4 to 8 weeks during treatment. This creates a completely natural, recurring need for testing. 2. Enormous momentum for "Reimbursement" (Refusion) To make money from a medical test in the USA, insurance companies must pay for it. They typically refuse to pay if a test is not backed by official guidelines or solid data. The fact that NCCN now recommends more frequent testing makes it much easier for Plus Therapeutics to convince the remaining American insurance companies to cover CNSide. This directly supports their 2026 goal of reaching 150 million covered lives in the USA. 3. "The Razor and Blade" business model The most attractive thing about CNSide is that it is not a "one-and-done" test. Since the guidelines now recommend testing every 4-8 weeks to monitor if the treatment works, CNSide becomes a continuous revenue stream per patient. More tests per patient mean higher and more predictable revenue (recurring revenue) for the company. In short: The news significantly reduces clinical risk and paves the way for commercial growth in 2026. 🤝🤞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt